Cell-based clinical trials using MSCs, MSC derivatives and other cells
| Registration date and execution date range DD-MM-YYYY | Study phase and recruitment status | ID and URL | Title | Cell type | Total participants n | Intervention or treatment | |
| Clinical trials based on MSCs | |||||||
| 1 | 14-02-2020; 20-02-2020 to 20-02-2021 | 0 Not recruiting | ChiCTR2000029816; http://www.chictr.org.cn/showproj.aspx?proj=49389 | Clinical study for cord blood mesenchymal stem cells in the treatment of acute novel coronavirus pneumonia (COVID-19) | UCB-MSCs; UCB-NK cells | 60 | Experimental groups: conventional treatment followed by i.v. infusion of 1) UCB-MSCs and 2) UCB-MSCs combined with UCB-NK cells Control group: conventional treatment |
| 2 | 14-02-2020; 20-02-2020 to 20-02-2021 | 0 Not recruiting | ChiCTR2000029817; http://www.chictr.org.cn/showproj.aspx?proj=49384 | Clinical study of cord blood NK cells combined with cord blood mesenchymal stem cells in the treatment of acute novel coronavirus pneumonia (COVID-19) | NK cells and UCB-MSCs | 60 | Experimental (high-dose) group: high-dose NK cells (>5×109) and MSCs (>5×109), i.v. infusion once every 2 days for a total of 5 times Conventional dose group: conventional dose NK cells (>3×109) and MSCs (>3×109), i.v. infusion once every 2 days for a total of 3 times Preventive dose group: preventive dose NK cells (>3×109) and MSCs (>3×109), i.v. infusion once every week for a total of 1 time |
| 3 | 07-02-2020; 15-01-2020 to 31-12-2022 | 0 Recruiting | ChiCTR2000029606; http://www.chictr.org.cn/showproj.aspx?proj=49146 | Clinical study for human menstrual blood-derived stem cells in the treatment of acute novel coronavirus pneumonia (COVID-19) | MenSCs | 63 | Experimental group A: Conventional treatment followed by i.v. infusion of MenSCs Control group A: conventional treatment Experimental group B: 1: Artificial liver therapy + conventional treatment 2: Artificial liver therapy followed by i.v. infusion of MenSCs + conventional treatment Control group B: conventional treatment |
| 4 | 07-02-2020; 06-02-2020 to 30-09-2020 | 2 Recruiting | NCT04269525; https://clinicaltrials.gov/show/NCT04269525 | Umbilical cord (UC)-derived mesenchymal stem cells (MSCs) treatment for the 2019-novel coronavirus (nCOV) pneumonia | UC-MSCs | 10 | Experimental group: UC-MSCs 3.3×107 cells per 50 mL per bag, 3 bags each time; UC-MSCs will be infused i.v. on the 1st, 3rd, 5th and 7th days after enrolment, once each day Control group: none specified |
| 5 | 05-02-2020; 31-01-2020 to 31-12-2020 | 0 Recruiting | ChiCTR2000029580; http://www.chictr.org.cn/showproj.aspx?proj=49088 | A prospective, single-blind, randomized controlled trial for ruxolitinib combined with mesenchymal stem cell infusion in the treatment of patients with severe 2019-nCoV pneumonia (novel coronavirus pneumonia, NCP) | MSCs | 70 | Experimental group: ruxolitinib combined with MSCs Control group: routine treatment |
| 6 | 27-01-2020; 21-01-2020 to 31-12-2021 | 1 Recruiting | NCT04252118; https://clinicaltrials.gov/show/NCT04252118 | Mesenchymal stem cell treatment for pneumonia patients infected with 2019 novel coronavirus | MSCs | 20 | Experimental group: 3.0×107 MSCs i.v. at days 0, 3 and 6 Control group: none specified |
| 7 | 14-02-2020; 16-02-2020 to 15-02-2022 | NA Not recruiting | NCT04273646; https://clinicaltrials.gov/ct2/show/NCT04273646 | Study of human umbilical cord mesenchymal stem cells in the treatment of novel coronavirus severe pneumonia | UC-MSCs | 48 | Experimental group: 4 times of UC-MSCs, 0.5×106 UC-MSCs·kg−1 body weight i.v. at days 1, 3, 5 and 7 Control group: none specified |
| 8 | 28-02-2020; 19-02-2020 to 20-02-2021 | 1 Recruiting | ChiCTR2000030300; http://www.chictr.org.cn/showprojen.aspx?proj=50022 | Umbilical cord mesenchymal stem cells (hucMSCs) in the treatment of high risk novel coronavirus pneumonia (COVID-19) patients | UC-MSCs | 9 | Experimental group: MSCs Control group: none specified |
| 9 | 26-02-2020; 14-02-2020 to 31-05-2020 | NA Not recruiting | ChiCTR2000030224; http://www.chictr.org.cn/showprojen.aspx?proj=49968 | Clinical study of mesenchymal stem cells in treating severe novel coronavirus pneumonia (COVID-19) | MSCs | 32 | Experimental group 1: critical group, intervention, injecting MSCs Experimental group 2: severe group, intervention, injecting MSCs Control group 3: control of the critical group, intervention, injecting normal saline Control group 4: control of the severe group, intervention, injecting normal saline |
| 10 | 24-02-2020; 17-02-2020 to 17-04-2020 | 0 Not recruiting | ChiCTR2000030173; http://www.chictr.org.cn/showprojen.aspx?proj=49229 | Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration | UC- MSCs | 60 | Experimental group: UC-MSCs Control group: Conventional treatment |
| 11 | 24-02-2020; 24-02-2020 to 31-05-2020 | 2 Not recruiting | ChiCTR2000030138; http://www.chictr.org.cn/showproj.aspx?proj=50004 | Clinical trial for human mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19) | UC-MSCs | 60 | Experimental group: i.v. injection of UC-MSCs Control group: routine treatment + placebo |
| 12 | 23-02-2020; 01-02-2020 to 31-08-2020 | NA Recruiting | ChiCTR2000030116; http://www.chictr.org.cn/showproj.aspx?proj=49901 | Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19) | UC-MSCs | 16 | Experimental group: different stem cell doses Control group: none specified |
| 13 | 22-02-2020; 01-03-2020 to 31-12-2021 | 0 Not recruiting | ChiCTR2000030088; http://www.chictr.org.cn/showproj.aspx?proj=49902 | Umbilical cord Wharton's jelly derived mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19) | UC-Wharton's jelly MSCs | 40 | Experimental group: i.v. injection of Wharton's jelly MSCs (1×106 MSCs·kg−1), cell suspension volume 40 mL Control group: i.v. 40 mL saline |
| 14 | 20-02-2020; 06-02-2020 to 05-02-2022 | NA Recruiting | ChiCTR2000030020; http://www.chictr.org.cn/showproj.aspx?proj=49812 | The clinical application and basic research related to mesenchymal stem cells to treat novel coronavirus pneumonia (COVID-19) | MSCs | 20 | Experimental group: case series, MSC therapy Control group: none specified |
| 15 | 18-02-2020; 30-01-2020 to 31-03-2020 | 1–2 Recruiting | ChiCTR2000029990; http://www.chictr.org.cn/showproj.aspx?proj=49674 | Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus pneumonia (COVID-19) | MSCs | 120 | Experimental group: MSCs Control group: saline |
| 16 | 28-02-2020; 28-02-2020 to 31-12-2021 | 1–2 Not recruiting | NCT04288102; https://clinicaltrials.gov/ct2/show/NCT04288102 | Treatment with mesenchymal stem cells for severe corona virus disease 2019 (COVID-19) | MSCs | 45 | Experimental group: 3 times of MSCs; if body weight ≥70 kg, 4.0×107 cells each time; if body weight <70 kg, 3.0×107 cells each time; i.v. at days 0, 3 and 6 Control group: saline containing 1% human serum albumin (solution used for MSCs), 3 times of placebo, i.v. at days 0, 3 and 6 |
| 17 | 24-02-2020; 24-02-2020 to 01-02-2021 | NA Recruiting | NCT04293692; https://clinicaltrials.gov/show/NCT04293692 | Therapy for pneumonia patients infected by 2019 novel coronavirus | UC-MSCs | 48 | Experimental group: conventional treatment plus 4 times of 0.5×106 UC-MSCs·kg−1 body weight suspended in 100 mL saline containing 1% human albumin, i.v. at days 1, 3, 5 and 7 Control group: conventional treatment plus 4 times of placebo (100 mL saline containing 1% human albumin), i.v. at days 1, 3, 5 and 7 |
| Clinical trials based on MSC derivatives | |||||||
| 1 | 04-02-2020; 05-02-2020 to 30-04-2021 | 0 Not recruiting | ChiCTR2000029569; http://www.chictr.org.cn/showproj.aspx?proj=49062 | Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled trial | UC-MSCs CM | 30 | Experimental group: conventional treatment combined with UC-MSCs CM Control group: conventional treatment |
| 2 | 19-02-2020; 15-02-2020 to 31-07-2020 | 1 Not recruiting | NCT04276987; https://clinicaltrials.gov/ct2/show/NCT04276987 | A pilot clinical study on inhalation of mesenchymal stem cells exosomes treating severe novel coronavirus pneumonia | AT-MSC exosomes | 30 | Experimental group: 5 times aerosol inhalation of MSC-derived exosomes, 2.0×108 nano vesicles per 3 mL at days 1, 2, 3, 4 and 5 Control group: none specified |
| 3 | 26-02-2020; 28-02-2020 to 31-05-2020 | 0 Not recruiting | ChiCTR2000030261; http://www.chictr.org.cn/showprojen.aspx?proj=49963 | A study for the key technology of mesenchymal stem cells exosomes atomization in the treatment of novel coronavirus pneumonia (COVID-19) | MSC exosomes | 26 | Experimental group: aerosol inhalation of exosomes Control group: blank |
| 4 | 03-03-2020; 31-01-2020 to 31-01-2021 | NA Not recruiting | ChiCTR2000030484; http://www.chictr.org.cn/showproj.aspx?proj=50263 | UC-MSCs and exosomes treating patients with lung injury following novel coronavirus pneumonia (COVID-19) | UC-MSCs and exosomes | 90 | Experimental groups: Group 1: UC-MSCs i.v. 5×107 cells each time, once a week, twice per course Group 2: UC-MSCs i.v. 5×107 cells each time, once a week, twice per course, a total of 2 courses; exosomes i.v. administration, 180 mg each time, once a day, 7 days per course, 2 courses in total Control group: same amount of placebo (stem cell solvent) |
| Clinical trials based on other cell types | |||||||
| 1 | 14-02-2020; 20-02-2020 to 20-02-2021 | 0 Not recruiting | ChiCTR2000029812; http://www.chictr.org.cn/showproj.aspx?proj=49374 | Clinical study for umbilical cord blood mononuclear cells in the treatment of acute novel coronavirus pneumonia (COVID-19) | UCBMCs | 60 | Experimental group: conventional treatment followed by i.v. UCBMC preparations Control group: conventional treatment |
| 2 | 05-02-2020; 05-02-2020 to 30-04-2021 | 0 Recruiting | ChiCTR2000029572; http://www.chictr.org.cn/showproj.aspx?proj=41760 | Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled clinical trial | UCBMCs | 30 | Experimental group: conventional treatment combined with UCBMCs Control group: conventional treatment |
| 3 | 17-02-2020; 24-02-2020 to 31-12-2024 | 1–2 Recruiting | NCT04276896; https://clinicaltrials.gov/show/NCT04276896 | Function and safety study of SARS-CoV-2 synthetic minigene vaccines | Autologous LV-DC vaccine or antigen-specific cytotoxic T-cells | 100 | Experimental group: 5×106 LV-DC vaccine or 1×108 cytotoxic T-cells as a single infusion via subcutaneous fluids or i.v. injection; may receive additional infusions Control group: none specified |
| 4 | 13-02-2020; 20-02-2020 to 30-12-2020 | 1 Recruiting | NCT04280224; https://clinicaltrials.gov/show/NCT04280224 | NK cells treatment for novel coronavirus pneumonia | NK cells | 30 | Experimental group: conventional treatment plus twice a week of NK cells (0.1–2×107 NK cells·kg−1 body weight) Control group: conventional treatment |
| 5 | 06-03-2020; 10-04-2020 to 10-11-2020 | 2 Not recruiting | NCT04299152; https://clinicaltrials.gov/ct2/show/NCT04299152 | Clinical application of stem cell educator therapy for the treatment of viral inflammation caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | CB-SCs | 20 | Experimental group: combination product: stem cell educator-treated mononuclear cells apheresis therapy circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent CB-SCs in vitro, and returns the “educated” autologous immune cells to the patient's circulation Control group: conventional treatment: regular treatments, only addressing their symptoms, such as reducing fever and cough |
| 6 | 28-02-2020; 01-03-2020 to 17-02-2021 | 0 Not recruiting | ChiCTR2000030088; http://www.chictr.org.cn/showproj.aspx?proj=49779 | Clinical trial for umbilical cord blood CIK and NK cells in the treatment of mild and general patients infected with novel coronavirus pneumonia (COVID-19) | CIK and NK cells | 90 | Experimental groups: CIK group: UCB CIK cells (1.6×108 cells·kg−1) injected twice every other day NK group: UCB NK cells (1.6×108 cells·kg−1) injected twice every other day Control group: conventional therapy |
MSCs: mesenchymal stem (stromal) cells; i.v.: intravenous; UCB: umbilical cord blood; NK: natural killer; MenSCs: mesenchymal stem cells derived from menstrual fluid; UC: umbilical cord; CM: conditioned medium; AT: adipose tissue; UCBMCs: umbilical cord blood-derived mononuclear cells; LV-DC: lentivirus dendritic cell; CB-SCs: cord blood stem cells; CIK: cytokine-induced killer.